New and Emerging Treatments for Rosacea

Rosacea is a common chronic inflammatory disorder that affects approximately 16 million Americans. The multifactorial pathophysiology of rosacea is not fully understood. Several new treatment options were recently US Food and Drug Administration approved or are in clinical trials. This paper reviews...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical dermatology 2015-12, Vol.16 (6), p.457-461
Main Authors: Gold, Lauren M., Draelos, Zoe Diana
Format: Article
Language:English
Subjects:
Administration, Topical
Brimonidine Tartrate - therapeutic use
Clinical Trials, Phase III as Topic
Dermatologic Agents - pharmacology
Dermatologic Agents - therapeutic use
Dermatology
Dicarboxylic Acids - therapeutic use
Drug Approval - statistics & numerical data
Female
Follow-Up Studies
Forecasting
Humans
Ivermectin - therapeutic use
Leading Article
Male
Medicine
Medicine & Public Health
Oxymetazoline - therapeutic use
Patient Satisfaction - statistics & numerical data
Pharmacology/Toxicology
Pharmacotherapy
Rosacea - diagnosis
Rosacea - drug therapy
Rosacea - epidemiology
Severity of Illness Index
Treatment Outcome
United States
United States Food and Drug Administration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rosacea is a common chronic inflammatory disorder that affects approximately 16 million Americans. The multifactorial pathophysiology of rosacea is not fully understood. Several new treatment options were recently US Food and Drug Administration approved or are in clinical trials. This paper reviews new treatment options including ivermectin, brimonidine, the new foam formulation of azelaic acid, and oxymetazoline. The potential role in therapy, patient selection, and adverse effects of these agents are discussed.
ISSN:1175-0561
1179-1888
DOI:10.1007/s40257-015-0156-2